Appendix 4D and Half Year Financial Report
Released
Released
Announcement PDF
Invion Limited
Appendix 4D
Half-year report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Invion Limited
76 094 730 417
For the half-year ended 31 December 2021
For the half-year ended 31 December 2020
2. Results for announcement to the market
$
Revenues from ordinary activities
up
4.4% to
1,298,560
Loss from ordinary activities after tax attributable to the owners of Invion
Limited
up
22.9% to
(1,046,509)
Loss for the half-year attributable to the owners of Invion Limited
22.9% to
(1,046,509)
up
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The loss for the consolidated entity after providing for income tax amounted to $1,046,509 (31 December 2020: $851,618).
3. Net tangible assets
Reporting
period
Cent
Net tangible assets per ordinary security
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Dividend reinvestment plans
Not applicable.
0.21
Previous
period
Cent
0.01
Invion Limited
Appendix 4D
Half-year report
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
10. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements were subject to a review by the auditors and the review report is attached as part of the Half year
ended.
11. Attachments
Details of attachments (if any):
The Half year ended of Invion Limited for the half-year ended 31 December 2021 is attached.
12. Signed
Signed ___________________________
Thian Chew
Chairman
Date: 22 February 2022
Invion Limited
ABN 76 094 730 417
Half year ended - 31 December 2021
Invion Limited
Contents
31 December 2021
Corporate directory
Directors' report
Auditor's independence declaration
Consolidated statement of profit or loss and other comprehensive income
Consolidated statement of financial position
Consolidated statement of changes in equity
Consolidated statement of cash flows
Notes to the consolidated financial statements
Directors' declaration
Independent auditor's review report to the members of Invion Limited
1
2
3
5
6
7
8
9
10
18
19
Invion Limited
Corporate directory
31 December 2021
Directors
Mr Thian Chew, Chairman and CEO
Mr Alan Yamashita, Non-executive Director
Mr Rob Merriel, Non-executive Director
Mr Alistair Bennallack, Non-executive Director
Company secretary
Claire Newstead-Sinclair (appointed on 1 November 2021)
Australia Business Number
76 094 730 417
Registered office
Level 4, 100 Albert Road, South Melbourne Vic 3205 Australia
P: (03) 8618 6843
E: investor@inviongroup.com
W: www.inviongroup.com
Share register
Link Market Service Limited
Locked Bag A14, Sydney South NSW 1235 Australia
P: 1300 554 474
F: (02) 9287 0303
W: www.linkmarketservices.com.au
Auditor
Grant Thornton, Melbourne, Australia
Stock exchange listing
Invion Limited shares are listed on the Australian Securities Exchange (ASX code:
IVX)
2
Invion Limited
Directors' report
31 December 2021
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'consolidated entity') consisting of Invion Limited (referred to hereafter as the 'company' or 'parent entity') and the entities
it controlled at the end of, or during, the half-year ended 31 December 2021.
Directors
The following persons were directors of Invion Limited during the whole of the financial half-year and up to the date of this
report, unless otherwise stated:
Mr Thian Chew, Chairman and CEO
Mr Alan Yamashita, Non-executive Director
Mr Rob Merriel, Non-executive Director
Mr Alistair Bennallack, Non-executive Director
Review of operations
Invion is a life sciences company that is leading the global research and development of PhotosoftTM technology for the
treatment of a range of cancers, atherosclerosis and infectious diseases. In the first half of the FY2022 financial year, the
Company made significant progress in proving up its Active Pharmaceutical Ingredient (API) INV043, expanding its exclusive
rights to the technology across multiple markets and successfully completing a $12.1 million capital raising.
The latest Proof-of-Concept (PoC) studies that were carried out by Invion’s research partner and world-leading research
organisation, Hudson Institute of Medical Research, showed a complete regression of triple negative breast cancer (TNBC)
in vivo following INV043 treatment.
The treatment appeared to have triggered an immune response as TNBC could not be re-established in treated
mice. Further, there was no apparent scarring or other indication of prior tumour presence, and no evidence of either primary
tumour or metastatic spread at autopsy.
Another significant development in the reported period was the expansion of Invion’s exclusivity agreement with RMW Cho
Group, the developer of PhotosoftTM technology, which will give Invion access to markets with more than 2.8 billion people.
Under the new agreement,x both parties will co-develop Photosoft™ for cancer and related diseases (Indications), pursuant
to which Invion will gain exclusive distribution rights to the technology in Asia Pacific1 (Territory) for the Indications.
To fund the expanded agreement and working capital, Invion undertook a Share Placement to institutional and sophisticated
investors and a Share Purchase Plan (SPP) that raised $12.1 million via the sale of new shares priced at 2.2 cents with one
free attaching option for every two new shares, exercisable at 4 cents and expiring 18 months from the issue date.
Outlook
Invion is building on its early success as it prepares to initiate clinical trials using its technology to treat cancers and advances
its research into atherosclerosis and infectious diseases. Cancer remains the primary focus of the Company. Invion and its
research partners, Hudson Institute and the Peter MacCallum Cancer Centre, are identifying target cancer indications for the
clinical trials and these details are expected to be announced to the market before the end of the 2022 financial year.
Meanwhile, Hudson Institute is working on further PoC studies, including a larger TNBC study (primary tumour model) and
a secondary study investigating the potential of INV043 using a metastatic model. The results from these studies are
expected in the coming half year.
It is expected that these efforts will pave the way for Invion to initiate clinical trials on more than one cancer indication by the
end of the calendar year. At this stage, the cancer targets for the initial human trials include basal cell carcinoma (BCC),
which accounts for the majority of skin cancers in Australia, and an anogenital cancer.
Invion is also expecting to release findings from early stage discovery work on atherosclerosis and infectious diseases in the
current calendar year. The results from this work will enable it to identify specific areas of the diseases to target before it
commences proof of concept studies on the targeted indications.
Financial performance
The loss for the consolidated entity after providing for income tax amounted to $1,046,509 (31 December 2020: $851,618).
1
The Territory includes all Asia Pacific countries excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea.
Invion’s rights with respect to development and distribution of the Photosoft™ technology in Australia and New Zealand will continue to be covered under the existing
agreements with RMW dated 31 August 2017.
3
Invion Limited
Directors' report
31 December 2021
Significant changes in the state of affairs
On 16 November 2021 Invion has entered into conditional agreements with RMW Cho Group Limited to co-develop
Photosoft™ technology for cancer and related diseases, pursuant to which Invion will gain exclusive distribution rights to the
Photosoft™ technology in Asia Pacific for the Indications.
On 22 November 2021, the Company issued 545,454,546 fully paid ordinary shares at an issue price of $0.022 per share.
There were no other significant changes in the state of affairs of the consolidated entity during the financial half-year.
Matters subsequent to the end of the financial half-year
No matter or circumstance has arisen since 31 December 2021 that has significantly affected, or may significantly affect the
consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial
years.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this directors' report.
This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.
On behalf of the directors
___________________________
Thian Chew
Chairman
22 February 2022
4
Collins Square, Tower 5
727 Collins Street
Melbourne Victoria 3008
Correspondence to:
GPO Box 4736
Melbourne Victoria 3001
T +61 3 8320 2222
F +61 3 8320 2200
E info.vic@au.gt.com
W www.grantthornton.com.au
Auditor’s Independence Declaration
To the Directors of Invion Limited
In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of
Invion Limited for the half-year ended 31 December 2021, I declare that, to the best of my knowledge and belief, there have
been:
a
no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
b
no contraventions of any applicable code of professional conduct in relation to the review
Grant Thornton Audit Pty Ltd
Chartered Accountants
M A Cunningham
Partner – Audit & Assurance
Melbourne, 22 February 2022
Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389
‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients
and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International
Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are
delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one
another and are not liable for one another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to
Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to
Grant Thornton Australia Limited.
Liability limited by a scheme approved under Professional Standards Legislation.
www.grantthornton.com.au
Invion Limited
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2021
Consolidated
31 December 31 December
Note
2021
2020
$
$
Revenue
5
1,298,560
1,244,321
Other income
6
80,013
89,368
7
(293,500)
(165,625)
(636,478)
(421,175)
(908,304)
-
(9,142)
(566,517)
(139,121)
(447,824)
(209,547)
(785,436)
(720)
(1,046,509)
(851,618)
-
-
(1,046,509)
(851,618)
-
-
(1,046,509)
(851,618)
Cents
Cents
Expenses
Cost of sales
Employee benefits expense
Depreciation and amortisation expenses
Administration & corporate expenses
Share-based payment expense
Research & development costs
Patent costs
8
Loss before income tax expense
Income tax expense
9
Loss after income tax expense for the half-year attributable to the owners of
Invion Limited
Other comprehensive income for the half-year, net of tax
Total comprehensive income for the half-year attributable to the owners of
Invion Limited
Basic earnings per share
Diluted earnings per share
23
23
(0.02)
(0.02)
(0.02)
(0.02)
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
6
Invion Limited
Consolidated statement of financial position
As at 31 December 2021
Consolidated
31 December
Note
2021
30 June 2021
$
$
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Other current assets
Total current assets
10
11
12
Non-current assets
Property, plant and equipment
Intangibles
Total non-current assets
13
Total assets
13,555,694
189,215
162,159
13,907,068
1,036,818
11,000
28,313
1,076,131
1,039
6,649,375
6,650,414
1,024
4,565,000
4,566,024
20,557,482
5,642,155
309,659
106,564
27,731
443,954
835,650
15,846
851,496
443,954
851,496
20,113,528
4,790,659
Liabilities
Current liabilities
Trade and other payables
Insurance premium funding
Provisions
Total current liabilities
14
Total liabilities
Net assets
Equity
Issued capital
Reserves
Accumulated losses
15
16
Total equity
146,543,659 130,956,127
3,211,040
2,429,194
(129,641,171) (128,594,662)
20,113,528
4,790,659
The above consolidated statement of financial position should be read in conjunction with the accompanying notes
7
Invion Limited
Consolidated statement of changes in equity
For the half-year ended 31 December 2021
Issued
capital
$
Consolidated
Balance at 1 July 2020
Options
reserves
$
130,555,435
Accumulated
losses
Total equity
$
$
1,990,206 (127,111,711)
5,433,930
Loss after income tax expense for the half-year
Other comprehensive income for the half-year, net of tax
-
-
(851,618)
-
(851,618)
-
Total comprehensive income for the half-year
-
-
(851,618)
(851,618)
375,867
8,396
-
(8,396)
601,471
(282,930)
-
375,867
601,471
(282,930)
2,300,351 (127,963,329)
5,276,720
Shares issued in lieu of employee compensation
Shares issued on exercise of options
Options granted to Directors and employees
Forfeiture of unvested options
Balance at 31 December 2020
130,939,698
Issued
capital
$
Consolidated
Balance at 1 July 2021
Options
reserves
$
130,956,127
Accumulated
losses
Total equity
$
$
2,429,194 (128,594,662)
4,790,659
Loss after income tax expense for the half-year
Other comprehensive income for the half-year, net of tax
-
-
(1,046,509)
-
(1,046,509)
-
Total comprehensive income for the half-year
-
-
(1,046,509)
(1,046,509)
15,530,622
-
-
15,530,622
56,910
421,175
264,900
152,681
(56,910)
-
421,175
264,900
152,681
-
3,211,040 (129,641,171)
20,113,528
Transactions with owners in their capacity as owners:
Contributions of equity, net of transaction costs (note 15)
Options expense for:
-Options granted to Directors and employees (note 24)
-Listed options issued to Lead Managers (note 24)
Options issued to Directors for Directors fee payables
Share option exercised
Balance at 31 December 2021
146,543,659
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes
8
Invion Limited
Consolidated statement of cash flows
For the half-year ended 31 December 2021
Consolidated
31 December 31 December
Note
2021
2020
$
$
Cash flows from operating activities
Receipts from customers
Payments to suppliers and employees
COVID-19 incentives
1,253,456
(2,392,050)
-
1,320,000
(1,507,136)
89,300
Interest received
Other revenue
(1,138,594)
13
88,000
(97,836)
68
-
Net cash used in operating activities
(1,050,581)
(97,768)
(2,250,000)
-
(2,250,000)
-
16,637,500
(818,043)
-
Net cash from financing activities
15,819,457
-
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the financial half-year
12,518,876
1,036,818
(97,768)
618,843
Cash and cash equivalents at the end of the financial half-year
13,555,694
521,075
Cash flows from investing activities
Payments for intangibles
13
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issue of shares
Share issue transaction costs paid
15
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes
9
Invion Limited
Notes to the consolidated financial statements
31 December 2021
Note 1. General information
The financial statements cover Invion Limited as a consolidated entity consisting of Invion Limited and the entities it controlled
at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Invion Limited's
functional and presentation currency.
Invion Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and
principal place of business are:
Registered office
Principal place of business
Level 4, 100 Albert Road,
South Melbourne, VIC 3205 Australia
692 High Street, East Kew, VIC 3102 Australia
A description of the nature of the consolidated entity's operations and its principal activities are included in the directors'
report, which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 22 February 2022.
Note 2. Corporate information
Invion Limited is a Company limited by shares incorporated in Australia whose shares have been publicly traded on the
Australian Securities Exchange since its listing on 15 February 2011 (ASX:IVX). Invion is a clinical-stage life-sciences
company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers,
atherosclerosis and infectious diseases. Through the Exclusion distribution and licencing agreements of 2017 and 2021,
Invion has been appointed exclusive licensee of Photosoft™ in Australia, New Zealand and all Asia Pacific countries
excluding China (other than Hong Kong), Macau, Taiwan, Japan and South Korea. The appointment has been made by
technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number
of unique and advanced technologies. Via 2017 R&D services agreement between the two entities, the research and clinical
trials of Photosoft™ on cancer treatments are funded by The Cho Group. The research on atherosclerosis and infectious
diseases will be co-funded by Invion and the Cho Group, through the recent Co-development Agreement in 2021.
Note 3. Significant accounting policies
These general purpose financial statements for the interim half-year reporting period ended 31 December 2021 have been
prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations
Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International
Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
These general purpose financial statements do not include all the notes of the type normally included in annual financial
statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended
30 June 2021 and any public announcements made by the company during the interim reporting period in accordance with
the continuous disclosure requirements of the Corporations Act 2001.
The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim
reporting period, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
Going concern
This financial report for the six months ended 31 December 2021 has been prepared on a going concern basis. The Group
incurred an operating loss after income tax of $1,046,509 (2020: $851,618) for the half-year. At 31 December 2021 the
Company had net assets of $20,113,528 (30 June 2021: $4,790,659) and a net current asset position of $13,463,114 (30
June 2021: $224,635). In common with other companies in the biotechnology sector, the Group’s operations are subject to
risks and uncertainty due primarily to the nature of the drug development and commercialisation.
10
Invion Limited
Notes to the consolidated financial statements
31 December 2021
Note 3. Significant accounting policies (continued)
The ability of the Group to continue as a going concern and meet its strategic objectives is principally dependent upon funds
continuing to be available for research and development expenditure and other principal activities. The Directors have
identified funding risk as an area of uncertainty and material risk impacting the Group due to the dependency on the R&D
Services Agreement with the Cho Group, and as similar to other companies in the biotechnology sector, recognise that
further capital may be required to fund the Group’s activities. During the half-year ended 31 December 2021, the Company
undertook two placements of ordinary shares to professional and sophisticated investors raising $16.7 million.
The Directors are satisfied that notwithstanding the material uncertainty, on the basis the Cho Group funding continues to be
made available, there is a reasonable basis to conclude that adequate cash is available to meet the liabilities and
commitments of the Group for a period of at least twelve months from the date of this report, and on that basis, are satisfied
that the going concern basis of preparation is appropriate. No adjustment has been made to recorded assets and liability
amounts and classifications should the group not continue as a going concern.
Note 4. Operating segments
Identification of reportable operating segments
The Invion Group has identified its operating segments based on the internal reports that are reviewed and used by the
Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in
determining the allocation of resources.
The Invion Group operates as a clinical-stage life sciences (drug development) group. At 31 December 2021, the Group had
operations in Australia only with its wholly owned subsidiary EpiTech Dermal Science Pty Ltd (previously IVX Cosmetics Pty
Ltd). The Group does not consider that the risks and returns of the Group have been or are affected by differences in either
the products or services it provides. The Group operates as one segment and as such in one geographical area. Group
performance is evaluated based on operating profit or loss and is measured consistently with profit or loss in the consolidated
financial statements. Group financing (including finance costs and finance income) and income taxes are managed on a
Group basis.
The information reported to the CODM is on a monthly basis.
Note 5. Revenue
Consolidated
31 December 31 December
2021
2020
$
$
R&D services fee- over time
Sale of Chlorine mixture - at point in time
1,298,560
-
1,222,321
22,000
Revenue
1,298,560
1,244,321
The above represents fees of $1,298,560 earned from RMW Cho Group for Research and Development services provided.
Note 6. Other income
Consolidated
31 December 31 December
2021
2020
$
$
Interest income
COVID-19 incentives
Reimbursement of expenses
13
80,000
68
89,300
-
Other income
80,013
89,368
11
Invion Limited
Notes to the consolidated financial statements
31 December 2021
Note 7. Administration & corporate expenses
Consolidated
31 December 31 December
2021
2020
$
$
Legal fees
Compliance costs
Consulting fees incl. accounting, business development
Insurance
Office, administration and corporate expenses
Rent and occupancy expenses
71,041
196,395
217,854
92,573
37,030
21,600
35,287
77,622
134,312
82,046
122,729
22,828
636,493
474,824
Note 8. Research & development costs
Consolidated
31 December 31 December
2021
2020
$
$
Pre-clinical trial costs
Consultancy fee - scientific and tech.
384,586
523,718
342,913
442,523
908,304
785,436
Note 9. Income tax expense
The Company has recorded nil tax expense for the period ended 31 December 2021 (2020: $nil).
Note 10. Current assets - cash and cash equivalents
Consolidated
31 December
2021
30 June 2021
$
$
Cash at bank and in hand
13,555,694
1,036,818
Note 11. Current assets - trade and other receivables
Consolidated
31 December
2021
30 June 2021
$
$
Trade receivables
Other receivables
185,054
4,161
11,000
-
189,215
11,000
Trade receivables at 31 December 2021 contain a contract asset of $9,054 which represents the right to consideration in
exchange for services performed under the R&D Service Agreement with RMW Cho Group.
12
Invion Limited
Notes to the consolidated financial statements
31 December 2021
Note 12. Current assets - Other current assets
Consolidated
31 December
2021
30 June 2021
$
$
Prepayments
162,159
28,313
Note 13. Non-current assets - intangibles
Consolidated
31 December
2021
30 June 2021
$
$
Intellectual property - at cost
Less: Accumulated amortisation
7,750,000
(1,100,625)
5,500,000
(935,000)
6,649,375
4,565,000
Reconciliations
Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
Consolidated
Photosoft
$
Total
$
Balance at 1 July 2021
Additions
Amortisation expense
4,565,000
2,250,000
(165,625)
4,565,000
2,250,000
(165,625)
Balance at 31 December 2021
6,649,375
6,649,375
Invion is developing PhotosoftTM technology as an improved next generation Photodynamic Therapy. The PhotosoftTM
commercialisation licence acquired in 2018 for $5,500,000 was recognised as an intangible asset and is being amortised
over a 20 year period. The PhotosoftTM commercialisation licence is being carried at the cost of the licence and distribution
agreement less accumulated amortisation.
During the current period, the company entered into the Co-development Agreement with RMW Cho Group (RMWCG) to
co-develop PhotosoftTM technology also referred to as Next Generation Photo Dynamic Therapy (NGPDT) for potential
applications in atherosclerosis and infectious diseases (including viral, bacterial, fungal and parasitic) ('the Indications').
Based on the terms of the Co-development Agreement, in consideration of the contributions of $2,250,000 made by the
company for the joint development of the NGPDT under this Agreement, RMWCG granted to Invion Limited an exclusive
licence to use the NGPDT IP (including any improvements thereof) and any inventions, and to distribute products and
procedures, in relation to the Indications in the Asia Pacific (excluding the Middle East, Russia and the specified territories
of China, Hong Kong, Macau and Taiwan) on the terms and conditions agreed between RMWCG and Invion Limited in the
Exclusive Distribution and Licence Agreement. This commercialisation licence is reflected as an intangible asset and is being
amortised over a 20-year period.
At each Balance Date, the Group assesses whether there is any indication that an intangible asset may be impaired. Where
an indicator of impairment exists, the Group makes an estimate of recoverable amount, and where the carrying amount of
an asset may exceed its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.
13
Invion Limited
Notes to the consolidated financial statements
31 December 2021
Note 13. Non-current assets - intangibles (continued)
Invion made a significant step forward in its research and development activities as it worked with its research partner,
Hudson Institute of Medical Research, to develop an improved API, which it called INV043. With the latest Proof-of-Concept
(PoC) studies carried out on INV043 showing great promise across a range of cancers, the company is expanding its
research and development activities to Atherosclerosis and Infectious Diseases. In light of significant progress in research
and development on cancer treatment using the Photosoft technology, management did not observe any indicators for
impairment to this carrying value. There have been no indicators of any technological obsolescence to the PhotosoftTM
technology. The Group assessed that there is no impact of COVID-19 on PhotosoftTM commercialisation licences.
Note 14. Current liabilities - trade and other payables
Consolidated
31 December
2021
30 June 2021
$
$
Trade payables
Accrued expenses
Director related accruals
Other payables
211,952
74,760
20,358
2,589
448,923
90,823
258,089
37,815
309,659
835,650
Note 15. Equity - issued capital
Consolidated
31 December
31 December
2021
30 June 2021
2021
30 June 2021
Shares
Shares
$
$
Ordinary shares - fully paid
6,416,513,644 5,539,542,295
146,543,659
130,956,127
Issue price
$
Movements in ordinary share capital
Details
Date
Shares
Balance
Placement of shares
Shares issued on exercise of options
Shares issued on exercise of options
Placement of shares
Placement of shares
Cost of raising capital
1 July 2021
30 September 2021
4 October 2021
5 October 2021
22 November 2021
10 December 2021
5,539,542,295
321,428,571
1,000,000
2,838,217
545,454,546
6,250,015
-
Balance
31 December 2021
6,416,513,644
$0.01
$0.01
$0.02
$0.02
$0.02
$0.00
130,956,127
4,500,000
13,943
42,967
12,000,000
137,500
(1,106,878)
146,543,659
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion
to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company
does not h
Share your feedback
Discover